ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
0,038 US$
0,00%
(0,00) 1D
1 tet, 4:00:00 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për ADAPY...
Hap
0,04 US$
I lartë
0,04 US$
I ulët
0,03 US$
Kapitalizimi i tregut
9,57 mln
Vëllimi mesatar
205,25 mijë
Vëllimi
229,54 mijë
Maksimumi 52-javor
0,28 US$
Minimumi 52-javor
0,00 US$
Beta
0,83
Aksionet në qarkullim
265,05 mln
Numri i punonjësve
272
Hap
0,04 US$
I lartë
0,04 US$
I ulët
0,03 US$
Kapitalizimi i tregut
9,57 mln
Vëllimi mesatar
205,25 mijë
Vëllimi
229,54 mijë
Maksimumi 52-javor
0,28 US$
Minimumi 52-javor
0,00 US$
Beta
0,83
Aksionet në qarkullim
265,05 mln
Numri i punonjësve
272
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
GlobeNewswire
·
15 minuta më parë
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
The Daily News | Texas' Oldest Newspaper
·
7 minuta më parë
Traders work on the floor of the NYSE in New York
24/7 Wall St.
·
11 minuta më parë
Peter Brandt Calls XRP a "Fool Coin" Just Before 473 Million XRP Lists on Nasdaq. Does Payment Utility Count for Anything in the Price?
Seeking Alpha
·
44 minuta më parë
SPYM ETF: S&P 500 Monthly Dashboard For October
Profili
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
Rreth Adaptimmune Therapeutics PLC - ADR
Drejtori ekzekutivAdrian Rawcliffe
Punonjësit272
Themeluar më2008
Selia-
Sektori-
Uebsajtiadaptimmune.com